(Image source from: edition.cnn.com)

The way we treat obesity around the world is changing quickly. In a significant move, the United States Food and Drug Administration (FDA) has given the green light to the Wegovy pill, a 25mg oral semaglutide that is taken once a day. This makes it the first oral GLP-1 receptor agonist approved for managing weight over the long term. Up until now, treatments based on GLP-1 that showed significant weight reduction were mainly injections, which made many patients hesitant to use them. This approval is particularly important because it relies on strong scientific proof showing weight loss that is similar to the injectable Wegovy, which has long been seen as the best option in the field of medical obesity treatment. The pill version is also authorized to help lower the chances of serious heart issues in adults who are obese or overweight and already have heart disease. Novo Nordisk plans to release the Wegovy pill in the US at the beginning of January 2026. The company had applied for approval of oral semaglutide 25mg for obesity to the European Medicines Agency (EMA) and other regulatory bodies during the second half of 2025.

In India, where obesity and type-2 diabetes are becoming more common and Ozempic (the injectable semaglutide produced by Novo Nordisk, the same company behind Wegovy) has only recently been introduced, this development is even more significant. It raises important questions about how soon oral GLP-1 medications might be available for Indian patients, how they might change the way we approach obesity treatment, and whether they can be affordable and used properly in a country that faces a high incidence of metabolic diseases. According to Novo Nordisk, the Wegovy pill is the first oral GLP-1 treatment specifically approved for weight loss. This decision is founded on the phase-3 OASIS clinical trial program, and it is supported by earlier trials known as STEP and PIONEER. In the OASIS-4 trial, adults who were either obese or overweight and had at least one other health issue lost an average of 16.6% of their weight over 64 weeks when they followed the treatment. One in three participants even lost 20% or more of their body weight. This level of weight loss is important because it is similar to what is achieved with the once-weekly injectable Wegovy. The safety matters were in line with what is already known about semaglutide, including side effects like nausea and vomiting.

GLP-1 receptor agonists function by decreasing hunger, making food leave the stomach more slowly, and enhancing blood sugar control. Significant studies published in major journals like The New England Journal of Medicine and The Lancet have indicated that semaglutide not only helps with weight loss but also reduces the risk of heart problems in patients who are at high risk. The World Health Organization (WHO) now classifies obesity as a long-term illness that needs ongoing treatment, rather than just lifestyle changes. An oral option could encourage more patients to stick with their treatment, especially those who are reluctant about getting injections. "Semaglutide has basically transformed our approach to managing obesity," states Dr. Ambrish Mithal, Group Chairman - Endocrinology & Diabetology, Max Healthcare, New Delhi. "We are witnessing weight loss along with a decrease in heart risks, better kidney functioning, and improved metabolic indicators. However, in our country, many individuals are hesitant to use injectables. If we can provide the same protection for organs and effectiveness in a tablet form, we can fill a significant gap in care. It becomes a simple part of a patient's daily routine, which is easily accessible."

India deals with both obesity and diabetes challenges, with warnings from the ICMR and WHO about higher heart risks even at lower body mass index (BMI) scores in Asian communities. With Ozempic injections now available in India, the approval of the Wegovy pill overseas hints at what might come next. Novo Nordisk has already sent the oral version to European authorities, indicating plans for global growth. "For the healthcare system in India, having an effective oral weight-loss medication could be crucial for widespread management," Dr. Mithal says. "It provides the privacy and convenience that easily fits into busy lives. We know semaglutide leads to weight loss and has a proven safety record. Many individuals who may hesitate to start an injection would probably accept a pill right away. This could enhance access to top-quality obesity care and help millions better manage their weight and avoid long-term health issues before they occur."

Nevertheless, getting approval in India will rely on the Central Drugs Standard Control Organisation (CDSCO), price discussions, and clear clinical guidelines. Specialists warn against using it for cosmetic weight loss and emphasize that it should only be prescribed under medical supervision. The FDA's approval of the Wegovy pill signifies a major shift in treating obesity by making a powerful GLP-1 therapy available in an easy-to-take oral form. For India, where metabolic illnesses are on the rise, this development highlights the importance of regulated and scientifically supported access to weight-loss medications. As injectable Ozempic starts to be used more widely in Indian clinics, the introduction of oral GLP-1 medications could further change the landscape of care, provided that safety, cost, and ethical prescribing practices are prioritized.